KOSDAQBiotech & Pharma115180

Qurient

₩24,800▲ 0.61%2026-10-02 close

Market Cap

₩929B

Turnover

₩1.4B

Volume

60,000 shares

Shares out.

37.5M

PER

—

PBR

50.0×

EPS

-₩1,061

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Clinical Data and Rights Offering at a Crossroads

Qurient remains a clinical-stage biotech with a clear loss structure, but the entry of Q901 and Q702 into efficacy-verification stages and a KRW 101.6 billion rights offering have emerged as the key variables shaping the company's path from the second half onward.

1
2025 consolidated revenue fell to KRW 6.98 billion from KRW 9.18 billion in 2024, while the operating loss widened to KRW 29.76 billion, the largest among the four years reviewed.
2
In Q2 2026, the operating loss reached KRW 12.84 billion and the net loss attributable to owners KRW 12.72 billion, both sharply wider than the prior quarter.
3
On September 4, the company disclosed a shareholder-allocated rights offering to issue 7.1 million new shares and raise KRW 101.6 billion, with proceeds earmarked primarily for dual-payload ADC development.
4
Core oncology assets mocaciclib (Q901) and adrixetinib (Q702) have entered efficacy-verification stages in target patient populations, and Phase 1 dose-escalation results for Q901 will be presented at ESMO 2026 in October.
5
Largest shareholder Dongkoo Bio & Pharma has made repeated follow-on investments since becoming the top shareholder in 2024, with its stake including affiliates reported at 19.56% as of February 2026.

Business structure

Qurient is a drug-development biotech spun off from the Pasteur Institute Korea in 2008, operating a 'Labless Research House' model that secures pipeline assets through partnerships with outside basic-research institutions rather than in-house labs.

Through strategic alliances with the Institut Pasteur in France and the Max Planck Institute in Germany, the company has introduced first-in-class candidates in oncology, antibacterials, and anti-inflammatory drugs.

The business is split into a research and development segment and a pharmaceutical distribution segment, aiming to monetize through out-licensing once clinical efficacy is proven, and through domestic distribution once regulatory approval is obtained.

The core oncology pipeline consists of the CDK7 inhibitor mocaciclib (Q901) and the Axl/Mer/CSF1R triple inhibitor adrixetinib (Q702), both in clinical trials across multiple solid tumors, with the oncology program including a joint research agreement with multinational pharmaceutical company MSD to develop combination therapy with the immuno-oncology drug Keytruda.

The pipeline has expanded further with the HER2-targeting dual-payload antibody-drug conjugate QP101 and a proteasome-inhibitor-based ADC payload platform from German subsidiary QLi5 Therapeutics.

Telacebec (Q203), a treatment for tuberculosis and Buruli ulcer, has been out-licensed to the TB Alliance and is undergoing registration-track clinical trials. In the CDK7 inhibitor competitive landscape, rivals include Carrick Therapeutics' samuraciclib (CT7001) and Exscientia's GTAEXS-617.

The largest shareholder is Dongkoo Bio & Pharma, which secured the top shareholder position through a third-party rights offering in 2024 and has continued to expand its stake since.

Earnings trend

Quarterly revenue · Operating profit

₩1.8B-₩6.8B25Q2₩1.7B-₩7B25Q3₩1.5B-₩9.3B25Q4₩1.9B-₩7.7B26Q1₩1.9B-₩12.8B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩8.5B-₩27.5B2022₩9B-₩23.2B2023₩9.2B-₩27.5B2024₩7B-₩29.8B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.8B	-₩6.8B	−366.4%
2025Q3	₩1.7B	-₩7B	−415.4%
2025Q4	₩1.5B	-₩9.3B	−606.2%
2026Q1	₩1.9B	-₩7.7B	−394.8%
2026Q2	₩1.9B	-₩12.8B	−672.7%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩8.5B	-₩27.5B	-₩25.5B	−324.4%	−82.2%	9.3%
2023	₩9B	-₩23.2B	-₩21.1B	−257.0%	−48.1%	5.5%
2024	₩9.2B	-₩27.5B	-₩24.1B	−299.3%	−48.1%	10.2%
2025	₩7B	-₩29.8B	-₩30.1B	−426.3%	−88.3%	58.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

2025 consolidated revenue came to KRW 6.98 billion, the lowest of the past four years compared with KRW 9.18 billion in 2024, KRW 9.03 billion in 2023, and KRW 8.47 billion in 2022.

The operating loss widened progressively from KRW 27.47 billion in 2022 and KRW 23.21 billion in 2023 to KRW 27.48 billion in 2024, reaching KRW 29.76 billion in 2025, the largest of the four years. The net loss attributable to owners also grew sharply to KRW 30.05 billion in 2025 from KRW 24.11 billion in 2024.

On a quarterly basis, the operating loss widened from KRW 6.76 billion in Q2 2025 to KRW 7.01 billion in Q3 and KRW 9.26 billion in Q4, eased somewhat to KRW 7.67 billion in Q1 2026, then widened sharply again to KRW 12.84 billion in Q2 2026.

The net loss attributable to owners followed a similar pattern, rising from KRW 6.06 billion to KRW 12.72 billion over the same window, with the most recent quarter's loss standing out.

According to company data compiled by a financial information provider, consolidated revenue in Q1 2026 rose 1.1% year-on-year, while the operating loss grew 14.0% and the net loss 27.7%, and the loss-widening trend continued into the second quarter.

One media outlet assessed that the widening operating loss in Q2 2026 reflects this structure directly, and while pipeline clinical progress is positive, financial strain could resurface if long-term development continues without external cash inflows such as licensing deals.

On the balance sheet, accumulated losses reduced total equity from KRW 52.68 billion in 2024 to KRW 39.19 billion in 2025, while liabilities rose from KRW 5.39 billion to KRW 22.80 billion over the same period, pushing the debt ratio up sharply from 10.2% to 58.2%.

Operating cash flow was negative across all four years, at negative KRW 28.67 billion in 2025, underscoring continued cash consumption from R&D spending.

Industry analysis

In the global oncology market, dealmaking around antibody-drug conjugate (ADC) technology remains active, and the mood around biotech investment in the United States has improved significantly, with active deal review across the industry, while ADC was again the central theme at the J.P. Morgan Healthcare Conference.

In the CDK7 inhibitor class, competing candidates include Carrick Therapeutics' samuraciclib (CT7001) and Exscientia's GTAEXS-617, with combination strategies with ADCs emerging as a common theme.

Indeed, first-line Trodelvy trial data from ASCENT-03 and ASCENT-04 presented at ASCO 2026 showed improved progression-free survival with Trodelvy in patients with homologous recombination repair mutations, adding to the body of evidence supporting combinations of CDK7 inhibitors with TOP1-based ADCs.

In the Priority Review Voucher (PRV) market, the public health emergency PRV program ended in 2023 and the rare pediatric disease PRV program has been mentioned as potentially ending in 2026, while recent PRV deals have been struck around the USD 150 million level, a factor relevant to the commercialization value of telacebec.

In the ADC platform services space, the world's top contract development and manufacturing organization Lonza showcased its Synaffix-based GlycoConnect and HydraSpace ADC conjugation technologies, presenting Qurient's QP101 as an actual partner case study, illustrating how a domestic biotech's dual-payload ADC technology is gaining attention from global CDMOs.

Amid this industry backdrop, Qurient is positioning itself by lowering reliance on any single pipeline asset and advancing multiple mechanisms in parallel.

Outlook

On September 4, the company disclosed a shareholder-allocated (with public offering of forfeited shares) rights offering to issue 7.1 million new shares and raise KRW 101.6 billion, with the record date for new share allocation set for October 13.

The proceeds will be focused on dual-payload antibody-drug conjugate research and development, with the company currently advancing HER2-targeting ADC QP101 as its lead program and planning to file an investigational new drug application next year.

Management stated that 2026 is a decisive turning point in which core pipeline assets are simultaneously entering the efficacy-verification stage, making clinical and commercial progress increasingly tangible.

An upcoming conference milestone is the ESMO 2026 meeting in Madrid in October, where the company plans to present Phase 1 dose-escalation results for the CDK7 inhibitor mocaciclib (Q901).

In pediatric oncology, mechanism-of-action research for mocaciclib in pediatric brain tumors was selected for an oral presentation at ISPNO 2026, the world's largest pediatric central nervous system tumor conference.

In the infectious disease pipeline, Phase 2 dosing of telacebec in 40 adult patients with Buruli ulcer has been completed, and the TB Alliance plans to conduct an expansion trial in 200 patients following a one-year observation period.

Beyond QP101, the company has also outlined a strategy of adding new dual-payload ADC candidates based on new target antibodies to expand the pipeline.

Valuation

PER

—

PBR

50.0×

ROE

-107.7%

EPS

-₩1,061

BPS

₩461

Dividend per share

₩0

Qurient is a clinical-stage biotech that has posted both operating and net losses in all four years reviewed, and given this loss-making structure, no price-earnings ratio can be calculated.

Its price-to-book ratio has been maintained above the upper end of the historical trading range for domestic drug-development biotechs, indicating the market is attaching a considerable premium to the future licensing value of its pipeline. The company pays no dividend, so dividend-related metrics carry little meaning.

The jump in the debt ratio from the 10% range in 2024 to the 50% range in 2025 reflects the combined effect of a shrinking equity base from accumulated losses and rising liabilities, and the rights offering disclosed in September has the potential to rebuild the equity base, though it also comes with dilution for existing shareholders.

Ultimately, the company's valuation appears to hinge far more on market expectations for clinical data readouts and licensing outcomes than on its current revenue or earnings scale.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Diversified Pipeline and Global Partnership Network

Qurient is simultaneously developing multiple mechanisms spanning oncology (Q901, Q702, QP101), infectious disease (Q203), and autoimmune disease (QLi5), reducing dependence on the success of any single asset.

The company has accumulated experience collaborating with global institutions, including joint research with MSD, cooperation with the U.S. National Cancer Institute, and the telacebec licensing deal with the TB Alliance.

Its dual-payload ADC technology has drawn international attention, including being showcased as a platform-service case study by Lonza, the world's largest CDMO.

Rights Offering Strengthens Financial Base

Once the KRW 101.6 billion shareholder-allocated rights offering disclosed in September is completed, the company would secure funds to sustain ongoing R&D spending, potentially easing near-term cash-burn concerns.

The company chose a shareholder-allocated structure over private mezzanine financing in an attempt to reduce future overhang risk from large blocks of stock awaiting sale. Proceeds are earmarked for expanding the dual-payload ADC pipeline including QP101, which could accelerate the pace of development.

Upcoming Conference and Clinical Data Catalysts

Phase 1 dose-escalation results for Q901 are scheduled to be presented at ESMO 2026 in October, and an oral presentation on pediatric brain tumors is planned at ISPNO 2026, continuing the accumulation of clinical evidence. Telacebec for Buruli ulcer has completed Phase 2 dosing and is moving into its next stage.

As these data points accumulate, they have the potential to serve as supporting material in licensing negotiations.

Bear factors

Simultaneous Revenue Decline and Widening Losses

2025 revenue declined year-over-year, while the operating loss and net loss both widened to the largest levels among the four years reviewed. The operating and net losses also expanded sharply quarter-over-quarter in Q2 2026, continuing the loss-widening trend.

With the revenue base still minimal, any improvement in profitability is likely to depend more on external events such as licensing deals than on organic revenue growth.

Dilution from the Rights Offering

The rights offering disclosed in September would add 7.1 million new shares to the existing base of roughly 37.5 million shares, diluting existing shareholders upon completion.

The company itself has noted that the shareholder-allocated structure carries the possibility of diluting the stakes of shareholders who do not participate. While subscription rights can be sold, the increase in shares outstanding has a structural effect on per-share metrics.

Deteriorating Balance Sheet and Reliance on External Funding

The debt ratio jumped sharply from 10.2% in 2024 to 58.2% in 2025, and equity shrank from KRW 52.68 billion to KRW 39.19 billion due to accumulated losses. Operating cash flow was negative in all four years reviewed, meaning continued external fundraising is unavoidable without internal cash generation.

Outside observers have also noted the possibility of renewed financial strain if cash inflows such as licensing deals do not materialize.

Risk factors

Clinical Success Uncertainty

Core pipeline assets such as Q901, Q702, and QP101 remain in Phase 1-2 trials, leaving uncertainty over whether efficacy and safety will be demonstrated in later-stage trials.

The CDK7 inhibitor class includes competing candidates from Carrick Therapeutics and Exscientia, creating potential competition in development speed and data quality. A clinical setback or delay could dampen licensing expectations.

Further Financing and Dilution Risk

With a minimal revenue base and consistently negative operating cash flow, the possibility that additional financing will be needed to sustain R&D spending even after the September rights offering cannot be ruled out.

The offering itself involves issuing 7.1 million new shares, making dilution for existing shareholders unavoidable, and repeated similar fundraising in the future could compound this dilution burden.

Largest shareholder Dongkoo Bio & Pharma's capacity for further investment may also be constrained by its own financial position.

Regulatory and Policy Change Risk

A significant portion of telacebec's commercialization value depends on the Priority Review Voucher (PRV) system, and there is uncertainty over the program's continuity given mentions that the rare pediatric disease PRV program could end in 2026.

PRV prices have also fluctuated with changes in supply, making it difficult to predict the market value at the actual time of receipt. Changes in the clinical trial and regulatory approval environment could also affect the development timeline.

What to watch next

October 13, 2026
This is the record date for new share allocation under the rights offering; the actual subscription rate and finalized issue price should be checked.
October 2026 (ESMO 2026, Madrid, Spain)
Phase 1 dose-escalation results for mocaciclib (Q901) are scheduled to be disclosed, potentially serving as supporting data for licensing negotiations, so the presentation content should be reviewed.
H2 2026 through 2027
The progress of the one-year follow-up and 200-patient expansion trial for telacebec in Buruli ulcer, along with the timing of any PRV award and related policy changes, should be monitored continuously.
2027
An IND filing for dual-payload ADC QP101 is planned; the actual filing timing and entry into clinical trials should be confirmed.
Mid-November 2026
This is the expected timing for the Q3 2026 earnings disclosure, when changes in the balance sheet and the profit-and-loss trend following the inflow of rights offering proceeds should be checked.

Overall view

Qurient has posted both operating losses and net losses in each of the four years from 2022 through 2025, and while 2025 revenue declined from the prior year, the operating loss widened further.

The operating and net losses expanded sharply again in Q2 2026 compared with the prior quarter, continuing the loss-widening trend.

Against this backdrop, the KRW 101.6 billion rights offering announced on September 4 has the potential to strengthen the company's financial base, but it also entails shareholder dilution, and the company's valuation appears to hinge far more on the outcome of pipeline licensing deals than on its current revenue or earnings.

Key events to monitor going forward include the Q901 data presentation at ESMO 2026 in October, the follow-up progress of telacebec's Phase 2 trial, and the planned IND filing for QP101.

Largest shareholder Dongkoo Bio & Pharma has continued to expand its investment since 2024, though its financial capacity may constrain further stake increases going forward.

Overall, the company is in a phase where the success of clinical and business-development events, rather than the timing of profit-and-loss improvement, stands as the central variable in its valuation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.